Nice backs Novartis’ lung cancer drug

pharmafile | May 20, 2016 | News story | |  NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation 

The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for lung cancer. 

Ceritinib has marketing authorisation in the UK as a treatment for anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC). Ceritinib is an ALK inhibitor. 

The company submission stated that the NHS list price is £4,923.45 for a 30-day supply. 

Lung cancer is the third most common cancer in the UK (2013), accounting for 13% of all new cases. It is the second most common cancer in both males (14% of all male cases) and females (12% of all female cases).

In 2013, there were 45,525 new cases of lung cancer in the UK: 24,481 (54%) in males and 21,044 (46%) in females. The crude incidence rate shows that there are 78 new lung cancer cases for every 100,000 males in the UK, and 65 for every 100,000 females.

Anjali Shukla

Related Content

FDA approves BMS’s Augtyro for lung cancer treatment

Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …


Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based …

Latest content